{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:46:20Z","timestamp":1792176380322,"version":"4.4.0"},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41433-026-04863-w","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:36:24Z","timestamp":1789407384000},"page":"2486-2487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comment on: \u2018Aflibercept 8\u2009mg in neovascular age-related macular degeneration and diabetic macular oedema\u2019"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7190-698X","authenticated-orcid":false,"given":"Abdullah","family":"Bousamri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"4863_CR1","doi-asserted-by":"publisher","unstructured":"Sivaprasad S, Stewart MW, Wykoff CC, Eichenbaum D, Korobelnik JF, Lanzetta P, et al. Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema: translating clinical trials into clinical practice. Eye. https:\/\/doi.org\/10.1038\/s41433-026-04779-5 (2026)","DOI":"10.1038\/s41433-026-04779-5"},{"key":"4863_CR2","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.3390\/jcm15124599","volume":"15","author":"A Bousamri","year":"2026","unstructured":"Bousamri A, Kana\u2019an M, Alharbi F, Alqudah N. Real-world outcomes of switching to aflibercept 8 mg in previously treated neovascular age-related macular degeneration: a systematic review and meta-analysis. J Clin Med. 2026;15:4599 https:\/\/doi.org\/10.3390\/jcm15124599.","journal-title":"J Clin Med"},{"key":"4863_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2025.08.022","volume":"133","author":"JF Korobelnik","year":"2026","unstructured":"Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: ninety-six-week results from the randomized phase 3 PULSAR trial. Ophthalmology. 2026;133:39\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.022.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04863-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04863-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04863-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:55:45Z","timestamp":1792173345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04863-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":3,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4863"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04863-w","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"10 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AB is an author of ref. [\n                      \n                      ], the meta-analysis discussed in this letter. No other competing interests are declared.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}